Diseases /
Multiple Myeloma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) [1]
Clinical Trials
There are 305 clinical trials for multiple myeloma, of which 261 are open and 44 are completed or closed. Of the trials that contain multiple myeloma as an inclusion criterion, 4 are early phase 1 (3 open), 112 are phase 1 (92 open), 60 are phase 1/phase 2 (52 open), 104 are phase 2 (91 open), 16 are phase 3 (15 open), 1 is phase 4 (1 open), and 8 are no phase specified (7 open).
IGH, FGFR3, and MAF are the most frequent gene inclusion criteria for multiple myeloma clinical trials [3].
Dexamethasone, cyclophosphamide, and lenalidomide are the most common interventions in multiple myeloma clinical trials.
Significant Genes in Multiple Myeloma
ABL1 +
ABL1 is an inclusion eligibility criterion in 25 clinical trials for multiple myeloma, of which 20 are open and 5 are closed. Of the trials that contain ABL1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 12 are phase 2 (10 open), and 2 are no phase specified (1 open) [3].
AFF1 +
AFF1 is an inclusion eligibility criterion in 19 clinical trials for multiple myeloma, of which 15 are open and 4 are closed. Of the trials that contain AFF1 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
AKT1 +
AKT1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
AKT2 +
AKT2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
AKT3 +
AKT3 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
ALK +
ALK is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
ARAF +
ARAF is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
ASXL1 +
ASXL1 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 3 are open and 1 is closed. Of the trials that contain ASXL1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
ATM +
ATM is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
ATR +
ATR is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
BCL2 +
BCL2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain BCL2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].
BCL6 +
BCL6 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain BCL6 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].
BCR +
BCR is an inclusion eligibility criterion in 24 clinical trials for multiple myeloma, of which 19 are open and 5 are closed. Of the trials that contain BCR status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 11 are phase 2 (9 open), and 2 are no phase specified (1 open) [3].
BIRC3 +
BIRC3 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
BRAF +
BRAF is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 8 are open and 2 are closed. Of the trials that contain BRAF status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [3].
BRCA1 +
BRCA1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
BRCA2 +
BRCA2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
BRIP1 +
BRIP1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
CALR +
CALR is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains CALR status and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) [3].
CBFB +
CBFB is an inclusion eligibility criterion in 7 clinical trials for multiple myeloma, of which 4 are open and 3 are closed. Of the trials that contain CBFB status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].
CCND1 +
CCND1 is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 7 are open and 3 are closed. Of the trials that contain CCND1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open) [3].
CCND3 +
CCND3 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 2 are open and 1 is closed. Of the trials that contain CCND3 status and multiple myeloma as inclusion criteria, 2 are phase 2 (1 open) and 1 is phase 3 (1 open) [3].
CDK4 +
CDK4 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
CDK6 +
CDK6 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain CDK6 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
CDKN2A +
CDKN2A is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
CDKN2C +
CDKN2C is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
CRKL +
CRKL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
CSF1R +
CSF1R is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
DEK +
DEK is an inclusion eligibility criterion in 20 clinical trials for multiple myeloma, of which 16 are open and 4 are closed. Of the trials that contain DEK status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
DNMT3A +
DNMT3A is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
EGFR +
EGFR is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
ELL +
ELL is an inclusion eligibility criterion in 19 clinical trials for multiple myeloma, of which 15 are open and 4 are closed. Of the trials that contain ELL status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
EZH2 +
EZH2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 0 are open and 2 are closed. Of the trials that contain EZH2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
FANCA +
FANCA is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCC +
FANCC is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCE +
FANCE is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCF +
FANCF is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCG +
FANCG is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCL +
FANCL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCM +
FANCM is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FBXW7 +
FBXW7 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FGF1 +
FGF1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF1 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF10 +
FGF10 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF10 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF11 +
FGF11 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF11 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF12 +
FGF12 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF12 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF13 +
FGF13 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF13 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF14 +
FGF14 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF14 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF16 +
FGF16 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF16 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF17 +
FGF17 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF17 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF18 +
FGF18 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF18 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF19 +
FGF19 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF19 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF2 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF20 +
FGF20 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF20 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF21 +
FGF21 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF21 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF22 +
FGF22 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF22 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF23 +
FGF23 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF23 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF3 +
FGF3 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF3 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF4 +
FGF4 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF4 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF5 +
FGF5 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF5 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF6 +
FGF6 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF6 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF7 +
FGF7 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF7 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF8 +
FGF8 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF8 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF9 +
FGF9 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF9 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGFR1 +
FGFR1 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain FGFR1 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [3].
FGFR2 +
FGFR2 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain FGFR2 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [3].
FGFR3 +
FGFR3 is an inclusion eligibility criterion in 31 clinical trials for multiple myeloma, of which 22 are open and 9 are closed. Of the trials that contain FGFR3 status and multiple myeloma as inclusion criteria, 8 are phase 1 (6 open), 5 are phase 1/phase 2 (4 open), and 18 are phase 2 (12 open) [3].
FGFR4 +
FGFR4 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain FGFR4 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
FLCN +
FLCN is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FLCN status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT3 +
FLT3 is an inclusion eligibility criterion in 26 clinical trials for multiple myeloma, of which 20 are open and 6 are closed. Of the trials that contain FLT3 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 13 are phase 2 (11 open), and 2 are no phase specified (1 open) [3].
FLT4 +
FLT4 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
HRAS +
HRAS is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain HRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 1 is phase 1/phase 2 (1 open) [3].
IDH1 +
IDH1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) [3].
IDH2 +
IDH2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain IDH2 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
IGH +
IGH is an inclusion eligibility criterion in 40 clinical trials for multiple myeloma, of which 27 are open and 13 are closed. Of the trials that contain IGH status and multiple myeloma as inclusion criteria, 11 are phase 1 (6 open), 6 are phase 1/phase 2 (4 open), 21 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
IKZF1 +
IKZF1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (1 open) [3].
JAK2 +
JAK2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (0 open) [3].
KDR +
KDR is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
KIT +
KIT is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 7 are open and 3 are closed. Of the trials that contain KIT status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 4 are phase 2 (4 open), and 1 is no phase specified (0 open) [3].
KMT2A +
KMT2A is an inclusion eligibility criterion in 21 clinical trials for multiple myeloma, of which 17 are open and 4 are closed. Of the trials that contain KMT2A status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
KRAS +
KRAS is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain KRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
MAF +
MAF is an inclusion eligibility criterion in 27 clinical trials for multiple myeloma, of which 18 are open and 9 are closed. Of the trials that contain MAF status and multiple myeloma as inclusion criteria, 8 are phase 1 (6 open), 4 are phase 1/phase 2 (3 open), and 15 are phase 2 (9 open) [3].
MAFB +
MAFB is an inclusion eligibility criterion in 18 clinical trials for multiple myeloma, of which 12 are open and 6 are closed. Of the trials that contain MAFB status and multiple myeloma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), and 10 are phase 2 (6 open) [3].
MAP2K1 +
MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAP2K2 +
MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAP2K4 +
MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAP3K1 +
MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAPK1 +
MAPK1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains MDM2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) [3].
MECOM +
MECOM is an inclusion eligibility criterion in 22 clinical trials for multiple myeloma, of which 18 are open and 4 are closed. Of the trials that contain MECOM status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 9 are phase 1 (7 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
MET +
MET is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain MET status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 7 clinical trials for multiple myeloma, of which 7 are open and 0 are closed. Of the trials that contain MLF1 status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].
MLLT1 +
MLLT1 is an inclusion eligibility criterion in 19 clinical trials for multiple myeloma, of which 15 are open and 4 are closed. Of the trials that contain MLLT1 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
MLLT10 +
MLLT10 is an inclusion eligibility criterion in 19 clinical trials for multiple myeloma, of which 15 are open and 4 are closed. Of the trials that contain MLLT10 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
MLLT3 +
MLLT3 is an inclusion eligibility criterion in 19 clinical trials for multiple myeloma, of which 15 are open and 4 are closed. Of the trials that contain MLLT3 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
MLLT4 +
MLLT4 is an inclusion eligibility criterion in 19 clinical trials for multiple myeloma, of which 15 are open and 4 are closed. Of the trials that contain MLLT4 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
MPL +
MPL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains MPL status and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
MTOR +
MTOR is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
MYC +
MYC is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 3 are open and 2 are closed. Of the trials that contain MYC status and multiple myeloma as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 2 (1 open) [3].
MYH11 +
MYH11 is an inclusion eligibility criterion in 7 clinical trials for multiple myeloma, of which 4 are open and 3 are closed. Of the trials that contain MYH11 status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].
NBN +
NBN is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
NF1 +
NF1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain NF1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
NF2 +
NF2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
NFKB2 +
NFKB2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NFKB2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 7 clinical trials for multiple myeloma, of which 7 are open and 0 are closed. Of the trials that contain NPM1 status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].
NRAS +
NRAS is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain NRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
NTRK1 +
NTRK1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
NTRK2 +
NTRK2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
NTRK3 +
NTRK3 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
NUP214 +
NUP214 is an inclusion eligibility criterion in 20 clinical trials for multiple myeloma, of which 16 are open and 4 are closed. Of the trials that contain NUP214 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
PBX1 +
PBX1 is an inclusion eligibility criterion in 13 clinical trials for multiple myeloma, of which 12 are open and 1 is closed. Of the trials that contain PBX1 status and multiple myeloma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is no phase specified (1 open) [3].
PDGFRA +
PDGFRA is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
PDGFRB +
PDGFRB is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
PHF6 +
PHF6 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
PIK3CA +
PIK3CA is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
PIK3R1 +
PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
POLD1 +
POLD1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
POLE +
POLE is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
PTCH1 +
PTCH1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
PTEN +
PTEN is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAD51 +
RAD51 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAF1 +
RAF1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
RET +
RET is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain RET status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
RHEB +
RHEB is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RHEB status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
ROS1 +
ROS1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPN1 +
RPN1 is an inclusion eligibility criterion in 22 clinical trials for multiple myeloma, of which 18 are open and 4 are closed. Of the trials that contain RPN1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 9 are phase 1 (7 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 2 are no phase specified (1 open) [3].
RUNX1 +
RUNX1 is an inclusion eligibility criterion in 9 clinical trials for multiple myeloma, of which 6 are open and 3 are closed. Of the trials that contain RUNX1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].
RUNX1T1 +
RUNX1T1 is an inclusion eligibility criterion in 7 clinical trials for multiple myeloma, of which 4 are open and 3 are closed. Of the trials that contain RUNX1T1 status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].
SF3B1 +
SF3B1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
SLX4 +
SLX4 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
SMO +
SMO is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain SMO status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
SRC +
SRC is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain SRC status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
SRSF2 +
SRSF2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains SRSF2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) [3].
STK11 +
STK11 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
TCF3 +
TCF3 is an inclusion eligibility criterion in 13 clinical trials for multiple myeloma, of which 12 are open and 1 is closed. Of the trials that contain TCF3 status and multiple myeloma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is no phase specified (1 open) [3].
TET2 +
TET2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
TP53 +
TP53 is an inclusion eligibility criterion in 26 clinical trials for multiple myeloma, of which 21 are open and 5 are closed. Of the trials that contain TP53 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 12 are phase 2 (11 open), and 2 are no phase specified (1 open) [3].
TSC1 +
TSC1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
TSC2 +
TSC2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain TSC2 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
VHL +
VHL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
WHSC1 +
WHSC1 is an inclusion eligibility criterion in 13 clinical trials for multiple myeloma, of which 10 are open and 3 are closed. Of the trials that contain WHSC1 status and multiple myeloma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
